KYTX · Categories · Form 4

KYTX - SEC Form 4 insider transactions

Kyverna Therapeutics Inc. (KYTX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for KYTX

• 40d
  Chief Financial Officer Grasso Marc was granted 10,000 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 40d
  Chief Executive Officer Biddle Warner Weston was granted 58,000 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 40d
  Officer Gehchan Naji was granted 18,000 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 53d
  Director Miller Andrew Craig was granted 11,006 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 59d
  Director Emany Sravan Kumar was granted 11,006 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 74d
  SEC Form 4 filed by Chief Technology Officer Pujols Mayobanex

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 102d
  Executive Chairperson Shaw Christi was granted 54,301 shares, increasing direct ownership by 326% to 70,935 units (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 130d
  Chief Technology Officer Walker Karen Marie exercised 23,998 shares at a strike of $4.83 and sold $292,776 worth of shares (23,998 units at $12.20) (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 299d
  SEC Form 4 filed by Chief Financial Officer Grasso Marc

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 328d
  Director Shaw Christi was granted 16,634 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 328d
  Director Seidenberg Beth C was granted 16,634 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 328d
  Director Spiegelman Daniel K was granted 16,634 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 328d
  Director Aktar Mert was granted 16,634 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 328d
  Director Clark Ian T was granted 16,634 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 328d
  Director Cohen Fred E was granted 16,634 shares (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 376d
  SEC Form 4 filed by Chief Executive Officer Biddle Warner Weston

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 376d
  Chief Financial Officer Jones Ryan Alexander was granted 12,000 shares, increasing direct ownership by 27% to 55,950 units (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 376d
  Chief Technology Officer Walker Karen Marie was granted 13,000 shares, increasing direct ownership by 135% to 22,636 units (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 431d
  SEC Form 4 filed by Director Shaw Christi

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 457d
  SEC Form 4 filed by Officer Gehchan Naji

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 549d
  SEC Form 4 filed by Director Aktar Mert

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 585d
  SEC Form 4 filed by Chief Executive Officer Biddle Warner Weston

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 585d
  SEC Form 4 filed by Director Shaw Christi

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 685d
  Chief Technology Officer Walker Karen Marie exercised 9,636 shares at a strike of $4.42 (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
• 697d
  Jones Ryan Alexander exercised 18,016 shares at a strike of $0.73, increasing direct ownership by 69% to 43,950 units (SEC Form 4)

  4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

Other KYTX categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends